Morgan Stanley Amends Integra Lifesciences (IART) Stake
Ticker: IART · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 917520
| Field | Detail |
|---|---|
| Company | Integra Lifesciences Holdings Corp (IART) |
| Form Type | SC 13G/A |
| Filed Date | Feb 9, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-stake
Related Tickers: IART
TL;DR
**Morgan Stanley still holds Integra Lifesciences stock, showing continued institutional interest.**
AI Summary
Morgan Stanley filed an amended Schedule 13G/A on February 9, 2024, indicating its ownership of Integra Lifesciences Holdings Corp (IART) common stock as of December 31, 2023. This filing, an amendment to a previous disclosure, shows that Morgan Stanley continues to hold a significant, though passive, stake in the medical instruments company. This matters to investors because it confirms a major institutional investor's continued interest in IART, potentially signaling confidence in the company's long-term prospects, even if the exact percentage of ownership isn't detailed in this snippet.
Why It Matters
This filing confirms Morgan Stanley's ongoing institutional ownership in Integra Lifesciences, which can be a positive signal for current and prospective shareholders.
Risk Assessment
Risk Level: low — This is a routine amendment filing by a large institutional investor, indicating no immediate significant risk or change in company fundamentals.
Analyst Insight
Investors should note Morgan Stanley's continued passive stake in Integra Lifesciences, but this filing alone doesn't provide enough detail to warrant a change in investment strategy without further analysis of the full filing's ownership percentage.
Key Players & Entities
- Morgan Stanley (company) — the institutional investor filing the SC 13G/A
- Integra Lifesciences Holdings Corp (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- February 9, 2024 (date) — the date the SC 13G/A was filed
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and 'Amendment No.2' in the filing.
Who is the 'subject company' in this filing?
The subject company is INTEGRA LIFESCIENCES HOLDINGS CORP, identified by 'COMPANY CONFORMED NAME: INTEGRA LIFESCIENCES HOLDINGS CORP' and CIK 0000917520.
Who is the 'filed by' entity in this document?
The entity that filed this document is MORGAN STANLEY, as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MORGAN STANLEY' and CIK 0000895421.
What is the 'Date Of Event which Requires Filing of this Statement'?
The date of the event which requires filing of this statement is December 31, 2023, as explicitly stated in the filing.
Under which rule is this Schedule 13G/A filed?
This Schedule 13G/A is filed under Rule 13d-1(b), as indicated by the 'x' next to '[x] Rule 13d-1(b)'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 regarding INTEGRA LIFESCIENCES HOLDINGS CORP (IART).